Shenzhen Glory Medical Co.,Ltd. (002551.SZ)
CNY 3.58
(-0.83%)
CNY 3.58
(-0.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -24.58 Million CNY | -28.63% |
| 2022 | -252.57 Million CNY | -38.16% |
| 2021 | 158.18 Million CNY | -53.58% |
| 2020 | 414.19 Million CNY | 142.6% |
| 2019 | 121.07 Million CNY | -33.53% |
| 2018 | 209.6 Million CNY | -2.81% |
| 2017 | 277.01 Million CNY | 2.64% |
| 2016 | 211.12 Million CNY | 10.95% |
| 2015 | 218.02 Million CNY | 23.89% |
| 2014 | 168.55 Million CNY | 43.32% |
| 2013 | 115.65 Million CNY | 35.14% |
| 2012 | 87.3 Million CNY | 48.81% |
| 2011 | 63.85 Million CNY | -2.88% |
| 2010 | 63.63 Million CNY | 37.15% |
| 2009 | 51.62 Million CNY | 45.04% |
| 2008 | 32.08 Million CNY | 22.73% |
| 2007 | 26.07 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -1.9 Million CNY | -103.32% |
| 2024 Q2 | 47.41 Million CNY | 156.48% |
| 2024 Q1 | 17.44 Million CNY | 118.77% |
| 2023 Q2 | 7.38 Million CNY | 43.8% |
| 2023 Q3 | 5.23 Million CNY | -29.14% |
| 2023 Q4 | -23.86 Million CNY | -555.97% |
| 2023 FY | - CNY | -28.63% |
| 2023 Q1 | 5.13 Million CNY | -86.11% |
| 2022 Q3 | -8.68 Million CNY | 73.84% |
| 2022 Q2 | -33.19 Million CNY | -684.29% |
| 2022 Q1 | 5.68 Million CNY | 184.0% |
| 2022 Q4 | 36.99 Million CNY | 525.99% |
| 2022 FY | - CNY | -38.16% |
| 2021 Q3 | 2.06 Million CNY | -84.32% |
| 2021 Q4 | 2 Million CNY | -2.88% |
| 2021 Q2 | 13.13 Million CNY | -88.0% |
| 2021 Q1 | 109.52 Million CNY | 22.02% |
| 2021 FY | - CNY | -53.58% |
| 2020 Q4 | 89.75 Million CNY | -1.04% |
| 2020 FY | - CNY | 142.6% |
| 2020 Q1 | 50.16 Million CNY | 35.55% |
| 2020 Q2 | 152.45 Million CNY | 203.91% |
| 2020 Q3 | 90.7 Million CNY | -40.51% |
| 2019 Q3 | 16 Million CNY | -68.81% |
| 2019 Q4 | 37.01 Million CNY | 131.3% |
| 2019 FY | - CNY | -33.53% |
| 2019 Q1 | 41.88 Million CNY | -24.05% |
| 2019 Q2 | 51.29 Million CNY | 22.46% |
| 2018 Q3 | 16.02 Million CNY | -79.35% |
| 2018 Q1 | 90.95 Million CNY | -9.74% |
| 2018 FY | - CNY | -2.81% |
| 2018 Q4 | 55.15 Million CNY | 244.23% |
| 2018 Q2 | 77.57 Million CNY | -14.72% |
| 2017 Q4 | 100.77 Million CNY | 2311.4% |
| 2017 Q2 | 30.72 Million CNY | -72.93% |
| 2017 Q3 | -4.55 Million CNY | -114.83% |
| 2017 FY | - CNY | 2.64% |
| 2017 Q1 | 113.5 Million CNY | 235.15% |
| 2016 Q1 | 91.95 Million CNY | 49.65% |
| 2016 Q3 | 39.16 Million CNY | -22.69% |
| 2016 Q4 | 33.86 Million CNY | -13.54% |
| 2016 FY | - CNY | 10.95% |
| 2016 Q2 | 50.66 Million CNY | -44.91% |
| 2015 Q4 | 61.44 Million CNY | -11.55% |
| 2015 Q2 | 60.02 Million CNY | 29.59% |
| 2015 Q1 | 46.31 Million CNY | -16.52% |
| 2015 FY | - CNY | 23.89% |
| 2015 Q3 | 69.47 Million CNY | 15.74% |
| 2014 FY | - CNY | 43.32% |
| 2014 Q2 | 54.17 Million CNY | 94.73% |
| 2014 Q4 | 55.48 Million CNY | 53.43% |
| 2014 Q3 | 36.16 Million CNY | -33.24% |
| 2014 Q1 | 27.81 Million CNY | -34.49% |
| 2013 Q2 | 41.3 Million CNY | 133.74% |
| 2013 FY | - CNY | 35.14% |
| 2013 Q3 | 22.66 Million CNY | -45.12% |
| 2013 Q4 | 42.46 Million CNY | 87.36% |
| 2013 Q1 | 17.66 Million CNY | -52.1% |
| 2012 Q4 | 36.89 Million CNY | 116.45% |
| 2012 Q1 | 20.98 Million CNY | 666.56% |
| 2012 Q2 | 15.55 Million CNY | -25.86% |
| 2012 Q3 | 17.04 Million CNY | 9.57% |
| 2012 FY | - CNY | 48.81% |
| 2011 Q4 | 2.73 Million CNY | -79.1% |
| 2011 Q2 | 21.76 Million CNY | 38.0% |
| 2011 Q1 | 15.77 Million CNY | 25.05% |
| 2011 FY | - CNY | -2.88% |
| 2011 Q3 | 13.09 Million CNY | -39.81% |
| 2010 Q3 | 16.58 Million CNY | -27.1% |
| 2010 Q1 | 7.56 Million CNY | 0.0% |
| 2010 Q2 | 22.74 Million CNY | 200.59% |
| 2010 Q4 | 12.61 Million CNY | -23.95% |
| 2010 FY | - CNY | 37.15% |
| 2009 FY | - CNY | 45.04% |
| 2008 FY | - CNY | 22.73% |
| 2007 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 4.03 Billion CNY | 100.61% |
| Realcan Pharmaceutical Group Co., Ltd. | 387.96 Million CNY | 106.338% |